| First Author | Pontier SM | Year | 2010 |
| Journal | Oncogene | Volume | 29 |
| Issue | 23 | Pages | 3374-85 |
| PubMed ID | 20305688 | Mgi Jnum | J:168172 |
| Mgi Id | MGI:4887305 | Doi | 10.1038/onc.2010.86 |
| Citation | Pontier SM, et al. (2010) Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 29(23):3374-85 |
| abstractText | Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction. |
